1nessAgency Insights

General Catalyst's decision to lead a $70 million funding round for a healthcare AI platform in 2026 marks one of the clearest signals yet that institutional capital has moved from experimenting with AI in healthcare to betting on it at scale , and the marketing implications for health systems and p

Integrated Home Care Services closed its acquisition of AI-enabled care coordination platform Dina Care on May 20, 2026, becoming the latest signal that home care benefit management is evolving from a cost center into a technology-driven infrastructure layer — and payer marketers who treat it as any

Publicis Groupe's acquisition of LiveRamp for $2.2 billion marks the moment healthcare marketers must confront an uncomfortable truth: the data strategies that worked for patient acquisition in 2024 are obsolete in an AI-agent era. The deal, announced May 18, 2026, values LiveRamp at $38.50 per shar

The FDA in May 2026 blocked approval of a melanoma treatment that extended life for a third of trial participants, a decision that fell during a year of unprecedented regulatory chaos under now-former Commissioner Marty Makary. The denial of RP1, a genetically engineered virus designed to destroy tu

The Becker's Hospital Review report from 2026 describes a Minnesota health system that reached the edge of permanent closure before securing a $205 million lifeline [1]. The specific system and funding source were not identified in the available headline summary, but the pattern is well-documented:

UnitedHealth Group, CVS Health, and Elevance Health are collectively redirecting billions of dollars from traditional insurance operations toward AI-powered platforms, predictive analytics engines, and data infrastructure [1]. UnitedHealth's Optum division alone generated over $100 billion in revenu

Epic Systems added 77 hospitals to its electronic health record client base — a market expansion that arrives as state and federal governments turn healthcare data infrastructure into an immigration enforcement tool, creating a collision between EHR vendor growth strategies and the trust required to

Healthcare executives who treat labor unrest as an HR problem are making a $50,000-per-vacant-position mistake. The news that roughly 3,000 nurses at Endeavor Health , the Chicago-based system formed from the 2023 merger of NorthShore University HealthSystem and Edward-Elmhurst Health , are seeking

Tampa General Hospital's revenue cycle leadership is declaring 2026 the year AI agents moved from theory to operational reality—a proclamation that arrives just as the Trump administration seeks to dismantle safety guardrails protecting patients from unvetted healthcare AI tools . This collision bet

The federal government is moving to strip away the guardrails that governed how AI tools are deployed inside electronic health records systems , and for healthcare marketers, the consequences are more direct than they appear. The Trump administration and HHS Secretary Robert F. Kennedy Jr. are advan

The physician employment revolution has reached a tipping point , and healthcare marketers who still build campaigns around independent doctor referrals are targeting a market that barely exists anymore. As of 2026, roughly 82% of U.S. physicians work as employees of hospitals, health systems, or co

A breakthrough HIV immunotherapy that could suppress the virus for years with a single infusion represents more than a clinical milestone. It marks the arrival of a new category of ultra-long-acting specialty therapies that will force healthcare marketers to abandon the chronic disease playbook they

DeepIntent, a healthcare-focused demand-side platform, named Ian Colley its chief marketing officer in April 2026, pulling a proven marketing executive from The Trade Desk just as the Trump administration considers pharmaceutical advertising restrictions that could reshape more than $10 billion in a

Men's health is having its loudest moment in decades. A May 2026 New York Times Magazine investigation into why so many men have become preoccupied with testosterone levels, masculinity, and optimization culture reflects a shift that healthcare marketers can no longer treat as fringe [1]. Telehealth

The FDA's 2026 decision to reopen regulatory pathways for flavored vaping products arrives at a moment when healthcare marketers face an equally disruptive shift: the marketing technology landscape has effectively stopped growing for the first time in 15 years. Both developments signal the end of an

The practical consequences are already visible. Makary had staked out positions on accelerated drug approvals and expanded access pathways, approaches that pharmaceutical and medical device companies had begun building into their go-to-market timelines for 2026 and 2027 launches [1]. An abrupt leade

OpenAI has moved well beyond chatbots. In 2026, the company has embedded its technology inside clinical workflows, revenue cycle operations, and patient communication platforms at major health systems across the United States. For healthcare marketing leaders, this is not a technology story. It is a

Knox Lane's agreement to take Cross Country Healthcare private for $437 million marks more than another PE roll-up in healthcare staffing. It signals the start of a new arbitrage: buying traditional healthcare service companies to gain access to their marketing infrastructure, client relationships,

Health systems that moved acute care into patient homes saw lower emergency department visits and reduced in-hospital mortality, according to a 2026 study published in JAMA Network Open . For healthcare marketers, this validates a fundamental shift: the hospital room is no longer the gold standard c

The Office of Personnel Management is pursuing unredacted health records from insurers covering millions of federal workers , and the fallout reaches far beyond Washington. Reported by KFF Health News in April and May 2026, the OPM data request represents the most aggressive federal incursion into e

CVS did not release granular Q1 2026 segment data at the time this article was prepared, but the company publicly raised its full-year guidance, a move that typically reflects management confidence in sustained margin improvement across its insurance, pharmacy, and care delivery businesses [1]. Aetn

The FDA's announcement names specific companies, specific compounds, and specific conditions. Three firms received national priority vouchers for psilocybin studies targeting treatment-resistant depression and major depressive disorder, and for methylone targeting PTSD [1]. DemeRx NB received cleara

The FDA's March 26, 2026 approval of Kresladi (marnetegragene autotemcel) for severe Leukocyte Adhesion Deficiency Type I marks a turning point not just for pediatric immunology, but for how rare disease marketers must operate. Rocket Pharmaceuticals now holds the first-ever FDA-approved gene therap

HCA Healthcare reported a $150 million revenue hit in Q1 2026 directly attributed to the lapse in Affordable Care Act subsidies—a figure that translates to roughly 100,000 patient visits at typical reimbursement rates. The nation's largest for-profit health system just quantified what most marketing

The FDA just approved a gene therapy for genetic hearing loss in 61 days—tied for the fastest biologics license application approval in modern agency history. For healthcare marketers in the rare disease and precision medicine space, this velocity changes patient identification timelines, reimbursem